UPDATED: Ex-Biogen CEO Jim Mullen steps back to the helm of a biotech, and once again he has a critical challenge to confront
A decade after he was pushed out of the top post at Biogen by a gang of activists, Jim Mullen is stepping back up to the helm of a biotech — this time looking to make history in gene editing.
Editas put out the word this morning that Mullen, who has been chairman of the company, will take the CEO position as Cindy Collins steps aside on February 15. Mullen is the third CEO to run the company since he was named chairman in 2018.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,000+ biopharma pros reading Endpoints daily — and it's free.